- Trials with a EudraCT protocol (732)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (11)
732 result(s) found for: Lymphocyte.
Displaying page 6 of 37.
EudraCT Number: 2009-014641-88 | Sponsor Protocol Number: STP-LYM-01-V01 | Start Date*: 2010-01-14 |
Sponsor Name:Medizinische Fakultaet der Technischen Universitaet Muenchen | ||
Full Title: Phase I/II dose-escalation study of the investigational trifunctional bispecific anti-CD20 x anti-CD3 antibody FBTA05 in combination with donor lymphocyte infusion (DLI) in patients with CD20 posit... | ||
Medical condition: CD20 positive chronic lymphocytic leukemia (CLL) low and high grade non-Hodgkin´s lymphoma (NHL) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2014-002984-14 | Sponsor Protocol Number: AC-064A201 | Start Date*: 2015-06-05 |
Sponsor Name:ACTELION Pharmaceuticals Ltd | ||
Full Title: A multicenter, randomized, double-blind, placebo-controlled, dose-response study to investigate the biological activity, safety, tolerability, and pharmacokinetics of ACT-334441 in subjects with sy... | ||
Medical condition: Systemic lupus erythematosus | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BG (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-000413-29 | Sponsor Protocol Number: RAMP08 | Start Date*: 2008-05-05 | |||||||||||
Sponsor Name:GITMO GRUPPO ITALIANO TRAPIANTO DI MIDOLLO OSSEO,CELLULE STAMINALI EMOPOIETICHE E TERAPIA CELLULARE - ONLUS | |||||||||||||
Full Title: Randomized study with methylprednisolone 1mg/kg/day for treatment of grade I acute GvHD | |||||||||||||
Medical condition: patients developing acute GvHD grade I | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003215-66 | Sponsor Protocol Number: MARAVITRANS | Start Date*: 2012-09-26 |
Sponsor Name:FIBio Hospital Universitario Ramón y Cajal | ||
Full Title: EFFECT OF MARAVIROC ON THE TRANSCRIPTION OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) IN RESTING CD4+ T LYMPHOCYTES IN PATIENTS ON ANTIRETROVIRAL TREATMENT WITH SUPPRESSED VIRAL LOAD | ||
Medical condition: HIV-infected patients | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-005713-39 | Sponsor Protocol Number: 42970 | Start Date*: 2014-09-02 |
Sponsor Name:St. Antonius Hospital | ||
Full Title: Response to influenza vaccination in lymphoma patients treated with CHOP and rituximab (RITUXIVAC) | ||
Medical condition: multiple myeloma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-007869-23 | Sponsor Protocol Number: PTC-MSC | Start Date*: 2009-06-26 |
Sponsor Name:AZIENDA OSPEDALIERA SAN GERARDO DI MONZA | ||
Full Title: Mesenchymal Stromal Cells (MSC) for the treatment of severe (grade II-IV) steroid-resistant Graft Versus Host Disease (GVHD): a phase I trial | ||
Medical condition: Graft versus Host disease GvHD steroid resistant | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000849-50 | Sponsor Protocol Number: MI-CP114 | Start Date*: 2017-12-12 |
Sponsor Name:MedImmune | ||
Full Title: A Phase I Randomized, Double-Blind Trial of the Safety and Immunogenicity of FluMist® A Live, Intranasal Influenza Virus Vaccine vs. Placebo in Immunocompromised Children Ages 5 Through 17 Years of... | ||
Medical condition: The prevention of Influenza Virus in Immunocompromised children ages 5 through 17 years of age. | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2005-002274-30 | Sponsor Protocol Number: BRD/05/11 | Start Date*: 2005-12-14 |
Sponsor Name:University College London | ||
Full Title: A Study to assess the safety, efficacy and tolerability of Rituximab(Mabthera) in combination with Plasma Exchange in patients with Acute Thrombotic Thrombocytopenia Purpura. | ||
Medical condition: Thrombotic Thrombocytopenia Purpura | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-004824-19 | Sponsor Protocol Number: ML21206 | Start Date*: 2008-08-08 |
Sponsor Name:Roche Austria GmbH | ||
Full Title: Bevacizumab in Chronic Lymphocytic Leukemia: a proof of concept study | ||
Medical condition: Chronic Lymphocytic Leukemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-001768-27 | Sponsor Protocol Number: P20/07 | Start Date*: 2020-04-27 | |||||||||||
Sponsor Name:CH Versailles | |||||||||||||
Full Title: "STUDY OF THE EFFICIENCY OF NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE" GERONIMO 19 | |||||||||||||
Medical condition: Patients aged 75 years and older with confirmed infection Covid19 and saturation SaO2≤ under 95% O2> 5 L / min disqualified from a care in the ICU | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001745-42 | Sponsor Protocol Number: 3045 | Start Date*: 2005-12-06 |
Sponsor Name:University of Liverpool and Royal Liverpool University Hospital | ||
Full Title: BCR-ABL Peptide Vaccination in Normal Subjects.An investigation in normal subjects with HLA-A3 and HLA-B8, as an extension of an identical study in patients with Chronic Myeloid Leukaemia. | ||
Medical condition: Healthy Subjects | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-020450-33 | Sponsor Protocol Number: IX-senesc2.0 | Start Date*: 2010-06-23 | |||||||||||
Sponsor Name:Institute of Specific Prophylaxis and Tropical Medicine | |||||||||||||
Full Title: Characterization of cellular and humoral immunity in the elderly upon vaccination with the purified inactivated Japanese Encephalitis Vaccine IXIARO® | |||||||||||||
Medical condition: The aim of this project is to investigate humoral and cellular immune responses before and after immunisation with the Japanese encephalitis vaccine IXIARO in subjects above 65 years of age in comp... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000284-24 | Sponsor Protocol Number: B5381012 | Start Date*: 2020-02-03 | |||||||||||
Sponsor Name:Pfizer Inc | |||||||||||||
Full Title: A RANDOMIZED COMPARATIVE STUDY ASSESSING THE SWITCHING BETWEEN PF-06410293 AND HUMIRA® IN COMBINATION WITH METHOTREXATE IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS. | |||||||||||||
Medical condition: Moderately to severely active Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004869-14 | Sponsor Protocol Number: CLL19H1 | Start Date*: 2019-04-15 | |||||||||||
Sponsor Name:Dept. of hematology, Herlev Hospital | |||||||||||||
Full Title: Peptide vaccination with PD-L1 and PD-L2 peptides in untreated chronic lymphatic leukemia. | |||||||||||||
Medical condition: Chronic lymphocytic leukemia with un-mutated IGHV | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013406-13 | Sponsor Protocol Number: GBM-DC-2009 | Start Date*: 2009-10-07 |
Sponsor Name:Masaryk University | ||
Full Title: First Line Therapy of Glioblastoma Multiforme with Surgical Resection, Irradiation Therapy, Temozolomide and Additional Tumour-Lysate Pulsed Dendritic Cell Vaccination. A Feasibility Phase II Study... | ||
Medical condition: Glioblastoma Multiforme | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003392-17 | Sponsor Protocol Number: BUSEQ-IPC2020-006 | Start Date*: 2021-02-17 |
Sponsor Name:Institut Paoli-Calmettes | ||
Full Title: SEQUENTIAL AND PERSONALIZED BUSULFAN ADMINISTRATION BY PHARMACOKINETICS IN ALLOGENIC GRAFT CONDITIONING FOR PATIENTS WITH MALIGNANT HEMOPATHIA NOT ELIGIBLE FOR STANDARD MYELOABLATIVE PACKAGIN | ||
Medical condition: Acute Leukemia Mielodysplasic Syndrome Myeloproliferative Neoplasm | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001603-16 | Sponsor Protocol Number: COLCHI-COVID | Start Date*: 2020-05-06 | |||||||||||
Sponsor Name:IDIVAL | |||||||||||||
Full Title: A RANDOMIZATION, MULTICENTRIC, OPEN-LABEL, CONTROLLED, CLINICAL TRIAL TO INVESTIGATE THE EFFECTIVENESS OF EARLY CHOLCHICINE ADMINISTRATION IN PATIENTS OVER 70 YEARS OF AGE WITH HIGH RISK OF DEVELOP... | |||||||||||||
Medical condition: Adult patients over 70 years of age diagnosed by COVID-19 with outpatient follow-up | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2023-000824-12 | Sponsor Protocol Number: B7981031 | Start Date*: 2023-09-06 |
Sponsor Name:Pfizer, Inc. | ||
Full Title: AN INTERVENTIONAL PK, PD, PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE PK AND PD OF MULTIPLE-DOSE RITLECITINIB IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA | ||
Medical condition: Alopecia Areata | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2008-005871-92 | Sponsor Protocol Number: Sahlgrenska/Hematology/2008:1 | Start Date*: 2009-02-05 | |||||||||||
Sponsor Name:Sahlgrenska University Hospital | |||||||||||||
Full Title: En fas 1 studie av effekt av Tysabri (natalizumab), en IgG4 humaniserad monoklonal antikropp specifik mot VLA-4 (integrin alfa-4), administrerad som infusion 1 gång/månad under 3 månader hos patie... | |||||||||||||
Medical condition: Chronic idiopathic thrombocytopenic purpura (ITP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003474-16 | Sponsor Protocol Number: Dukoral+Vivotif | Start Date*: 2015-08-26 |
Sponsor Name:Helsinki University Hospital | ||
Full Title: Immunity elicited by concomitant administration of oral typhoid fever (Vivotif®) and cholera (Dukoral®) vaccines | ||
Medical condition: Healthy volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
